Being consistent with the study for high-risk gliomas which showed that MGMT promoter methylation predicts better survival outcomes [30], our finding not only provides evidence that alteration of the epigenome is an important step in cancer progression, but also opens new windows of opportunities in personalized medicine for CRPC patients. Here, MGMT is linked to central nervous system cancer.